213 related articles for article (PubMed ID: 36927210)
21. [PSMA-based theranostics for prostate cancer : From imaging to treatment].
Ilhan H; la Fougère C; Krause BJ
Urologe A; 2020 May; 59(5):617-625. PubMed ID: 32377764
[TBL] [Abstract][Full Text] [Related]
22. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
23. Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen.
Kulkarni HR; Singh A; Langbein T; Schuchardt C; Mueller D; Zhang J; Lehmann C; Baum RP
Br J Radiol; 2018 Nov; 91(1091):20180308. PubMed ID: 29762048
[TBL] [Abstract][Full Text] [Related]
24. Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer.
Plichta KA; Graves SA; Buatti JM
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829977
[TBL] [Abstract][Full Text] [Related]
25. Clinical Translation and First In-Human Use of [
Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
[TBL] [Abstract][Full Text] [Related]
26. Prostate-specific membrane antigen targeted PET/CT for recurrent prostate cancer: a clinician's guide.
Young S; Liu W; Zukotynski K; Bauman G
Expert Rev Anticancer Ther; 2021 Jun; 21(6):641-655. PubMed ID: 33476253
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine.
Bouchelouche K; Choyke PL
Curr Opin Oncol; 2016 May; 28(3):216-21. PubMed ID: 26967720
[TBL] [Abstract][Full Text] [Related]
28. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.
Pouliot F; Beauregard JM; Saad F; Trudel D; Richard PO; Turcotte É; Rousseau É; Probst S; Kassouf W; Anidjar M; Camirand Lemyre F; Bouvet GF; Neveu B; Tétu A; Guérin B
BJU Int; 2022 Sep; 130(3):314-322. PubMed ID: 34674367
[TBL] [Abstract][Full Text] [Related]
29. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
Lenis AT; Pooli A; Lec PM; Sadun TY; Johnson DC; Lebacle C; Fendler WP; Eiber M; Czernin J; Reiter RE; Calais J
Eur Urol Oncol; 2022 Oct; 5(5):544-552. PubMed ID: 32958451
[TBL] [Abstract][Full Text] [Related]
30. Antibodies targeting Prostate-Specific Membrane Antigen positive prostate cancer: from diagnostic imaging to theranostics.
Roumeguère T; Aoun F; Albisinni S; Mjaess G
Curr Opin Oncol; 2021 Sep; 33(5):500-506. PubMed ID: 34230440
[TBL] [Abstract][Full Text] [Related]
31. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
Chatalic KL; Heskamp S; Konijnenberg M; Molkenboer-Kuenen JD; Franssen GM; Clahsen-van Groningen MC; Schottelius M; Wester HJ; van Weerden WM; Boerman OC; de Jong M
Theranostics; 2016; 6(6):849-61. PubMed ID: 27162555
[TBL] [Abstract][Full Text] [Related]
32.
Jadvar H; Colletti PM
Br J Radiol; 2018 Nov; 91(1091):20170948. PubMed ID: 29630398
[TBL] [Abstract][Full Text] [Related]
33. Head-To-Head Comparison of
Zhao G; Ji B
AJR Am J Roentgenol; 2022 Sep; 219(3):386-395. PubMed ID: 35441529
[No Abstract] [Full Text] [Related]
34. Uncovering the invisible-prevalence, characteristics, and radiomics feature-based detection of visually undetectable intraprostatic tumor lesions in
Zamboglou C; Bettermann AS; Gratzke C; Mix M; Ruf J; Kiefer S; Jilg CA; Benndorf M; Spohn S; Fassbender TF; Bronsert P; Chen M; Guo H; Wang F; Qiu X; Grosu AL
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1987-1997. PubMed ID: 33210239
[TBL] [Abstract][Full Text] [Related]
35. PSMA PET and Radionuclide Therapy in Prostate Cancer.
Bouchelouche K; Turkbey B; Choyke PL
Semin Nucl Med; 2016 Nov; 46(6):522-535. PubMed ID: 27825432
[TBL] [Abstract][Full Text] [Related]
36. PSMA-Targeting Imaging and Theranostic Agents-Current Status and Future Perspective.
Debnath S; Zhou N; McLaughlin M; Rice S; Pillai AK; Hao G; Sun X
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163083
[TBL] [Abstract][Full Text] [Related]
37. EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [
Fanti S; Briganti A; Emmett L; Fizazi K; Gillessen S; Goffin K; Hadaschik BA; Herrmann K; Kunikowska J; Maurer T; MacLennan S; Mottet N; Murphy DG; Oprea-Lager DE; O'Sullivan JM; Oyen WJG; Rouvière O; Sartor O; Stenzl A; Van Poppel H; Walz J; Witjes W; Bjartell A
Eur Urol Oncol; 2022 Oct; 5(5):530-536. PubMed ID: 35697600
[TBL] [Abstract][Full Text] [Related]
38. A prospective intra-individual comparison of [
Lawal IO; Mokoala KMG; Mahapane J; Kleyhans J; Meckel M; Vorster M; Ebenhan T; Rösch F; Sathekge MM
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):134-142. PubMed ID: 32424485
[TBL] [Abstract][Full Text] [Related]
39. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U
J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298
[TBL] [Abstract][Full Text] [Related]
40. How accurate is
Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
